HLB Pharmaceutical Co. Ltd (047920) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of HLB Pharmaceutical Co. Ltd KRW 2,295, price KRW 7,400, upside -69.0%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch HLB Pharmaceutical Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 6,170 KRW – 41,100 KRW · fair‑value band 1,721 KRW – 2,868 KRW · the 7,400 KRW price screens above the 2,295 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow HLB Pharmaceutical Co. in your weekly email
Every Wednesday you see whether HLB Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea.
Show more
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.
Stock analysis
HLB Pharmaceutical Co. Ltd (047920) currently trades at 7,400 KRW, while our model-based Fair Value estimate is 2,295 KRW, implying the stock looks roughly 222.5% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 6,146 KRW per share, and 0 of the 15 models we run sit above the 7,400 KRW price.
Bear case: the Economic Profit group reads lowest at 465.51 KRW, and 15 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 1,721 KRW (bear) to 2,868 KRW (bull), the price of 7,400 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
HLB Pharmaceutical Co. Ltd reported revenue of 206B KRW in FY2025 versus 62.9B KRW in FY2021, a compound +34.5%/yr. Reported net income was 4.6B KRW in FY2025.
Key figures
Market cap 243B KRW (≈ $178M) · P/S ratio 18.4 · Net margin 2.2% · Return on equity −39.8% · Return on assets (EBIT) −2.8% · Operating margin 1.6% · Revenue growth (YoY) +89.5% · EPS growth (YoY) −55.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 65% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −69%, 047920 screens richer than that median.
Fair Value models
Bear 1,721 KRWFair Value 2,295 KRWBull 2,868 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+50.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.3%
Start year 2020 (pandemic). Over 10 years: +27.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.33% vs 11%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → 1%
Compare HLB Pharmaceutical Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 628 stocks
Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−69% · Bottom 25%
Profitability
Return on assets−12% · Bottom 25%
Net margin (TTM)−53% · Bottom 25%
Operating margin (TTM)2% · Below median
Growth and dividend
Revenue growth90% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.01× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)100· sector 20
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is HLB Pharmaceutical Co. Ltd (047920) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,295 KRW versus a price of 7,400 KRW, about −69% upside (overvalued).
What is the fair value of 047920?
Our model-based fair value for HLB Pharmaceutical Co. Ltd is 2,295 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,400 KRW.
What is the quality score of 047920?
HLB Pharmaceutical Co. Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLB Pharmaceutical Co. Ltd (047920)?
Our model-based price target is the fair value of 2,295 KRW (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 1,721 KRW, optimistic scenario 2,868 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the HLB Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 2,295 KRW, about −69% upside versus a price of 7,400 KRW (overvalued). Cautious scenario 1,721 KRW, optimistic scenario 2,868 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of HLB Pharmaceutical Co. Ltd (047920)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLB Pharmaceutical Co. Ltd it is 2,295 KRW per share (as of Sep 24, 2026), against a price of 7,400 KRW. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is HLB Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 047920 trades above its calculated fair value: price 7,400 KRW, fair value 2,295 KRW, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 047920?
No. The price is what the market pays today (7,400 KRW); the fair value is what the company's own numbers justify (2,295 KRW). For HLB Pharmaceutical Co. Ltd the two are 5,105 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HLB Pharmaceutical Co. Ltd worth?
The market values HLB Pharmaceutical Co. Ltd at about 243B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,400 KRW; our models calculate a fair value of 2,295 KRW per share.
What do the bullish and bearish scenarios say about 047920?
Our models span a range for HLB Pharmaceutical Co. Ltd: cautious scenario 1,721 KRW, base 2,295 KRW, optimistic 2,868 KRW per share (as of Sep 24, 2026, price 7,400 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HLB Pharmaceutical Co. Ltd (047920)?
Balance-sheet figures for HLB Pharmaceutical Co. Ltd (as of Sep 24, 2026): return on equity −39.8%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 047920 from its 52-week high?
HLB Pharmaceutical Co. Ltd trades at 7,400 KRW, about 65% below its 52-week high of 20,900 KRW and 20% above the low of 6,170 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,295 KRW is for.
Which stocks are comparable to HLB Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLB Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 7,400 KRW, calculated fair value 2,295 KRW (−69%), Quality Score 40/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 047920 calculated?
We run HLB Pharmaceutical Co. Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,295 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. HLB Pharmaceutical Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLB Pharmaceutical Co. Ltd (047920)?
The closing price on Sep 23, 2026 was 7,400 KRW. Our model-based fair value is 2,295 KRW, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLB Pharmaceutical Co. Ltd right now?
The price sits above even our optimistic bull case (2,868 KRW). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of HLB Pharmaceutical Co. Ltd
How large is the market capitalisation of HLB Pharmaceutical Co. Ltd (047920)?
The market capitalisation of HLB Pharmaceutical Co. Ltd is 243B KRW (≈ $178M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HLB Pharmaceutical Co. Ltd (047920)?
The price-to-sales ratio of HLB Pharmaceutical Co. Ltd is 18.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of HLB Pharmaceutical Co. Ltd (047920)?
The net margin of HLB Pharmaceutical Co. Ltd is 2.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HLB Pharmaceutical Co. Ltd (047920)?
The return on equity (ROE) of HLB Pharmaceutical Co. Ltd is −39.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HLB Pharmaceutical Co. Ltd (047920)?
On an EBIT basis the return on assets of HLB Pharmaceutical Co. Ltd is −2.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLB Pharmaceutical Co. Ltd (047920)?
The operating margin of HLB Pharmaceutical Co. Ltd is 1.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HLB Pharmaceutical Co. Ltd (047920)?
Revenue at HLB Pharmaceutical Co. Ltd is growing +89.5% versus a year earlier (3y avg +24.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HLB Pharmaceutical Co. Ltd (047920)?
Earnings per share at HLB Pharmaceutical Co. Ltd are growing −55.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HLB Pharmaceutical Co. Ltd (047920) generate?
The free cash flow of HLB Pharmaceutical Co. Ltd is −6.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HLB Pharmaceutical Co. Ltd (047920) carry?
The net debt of HLB Pharmaceutical Co. Ltd is 7.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch HLB Pharmaceutical Co. Ltd in the live analysis
One click puts HLB Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
